ABL1 and acute lymphoblastic leukemia: Our data also show that Hsp32-targeting drugs induce apoptosis and growth arrest in ALL cells and synergize with BCR/ABL1 TKI and with bendamustin in producing growth inhibition in imatinib-sensitive and imatinib-resistant ALL cells.